drugset / Trial / NCT00718471

STEMI Treated With Primary Angioplasty and Intravenous Lovenox or Unfractionated Heparin (UFH)

NCT00718471 ↗

Phase 3 Completed 910 enrolled Assistance Publique - Hôpitaux de Paris
RandomizedParallel-groupOpen-labelTreatment

Summary

Randomized evaluation of enoxaparin (0.5mg/kg IV) versus UFH (50-70IU/kg with GPIIb/IIIa inhibitors; 70-100IU without GPIIb/IIIa inhibitors). Anticoagulation can be continued after the procedure using the same agents as those allocated per randomization (enoxaparin SC, UHF IV or SC)

Timeline

Start
2008-08
Primary completion
2010-03
Completion
2010-08

Outcome

Missed primary endpoint

paper (relative risk [RR] 0·83, 95% CI 0·68-1·01, p=0·06). PMID 21856483 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Enoxaparin sodium Other / unclassified 0.5 mg/kg Intravenous
Comparator HEPARIN CALCIUM Other / unclassified 50 iu/kg Intravenous
Comparator HEPARIN CALCIUM Other / unclassified 70 iu/kg Intravenous
Comparator HEPARIN CALCIUM Other / unclassified 100 iu/kg Intravenous